Testing a new combo treatment for newly diagnosed brain lymphoma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old, with newly diagnosed primary CNS lymphoma confirmed by biopsy/tissue testing
- You have not had prior lymphoma treatment (steroid-only treatment is allowed)
- Your MRI shows a visible lymphoma area that measures at least 1 cm (shortest measurement)
- You can have repeat scans and a spinal tap (lumbar puncture), and you can swallow pills
- Blood tests are strong enough: kidneys, liver, and blood counts meet the trial’s cutoff levels
- You must be able to sign consent and follow birth control rules to avoid pregnancy during treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.